fda warning letter glp-1 october 2025 issues 30 letters to online compounders FDA Targets Telehealth Compounded GLP-1

GLP-1s including Semaglutide (sold under the brand name Ozempic) and Tirzepatide can sometimes lead to reduced fluid intake or changes in digestion, which in turn dehydrate the skin

Weight Loss Comparison: Injectable Semaglutide (Wegovy 2.4 mg weekly): Average weight loss: 14.9% of body weight Duration: 68 weeks Patients losing 5%+: 86.4% Patients losing 10%+: 69.1% Patients losing 15%+: 50.5% Injectable Tirzepatide (Zepbound 15 mg weekly): Average weight loss: 22.5% of body weight Duration: 72 weeks Patients losing 5%+: 96% Patients losing 10%+: 89% Patients losing 15%+: 78% Patients losing 20%+: 63% Oral Semaglutide (Rybelsus 14 mg daily): Average weight loss: 3-5% of body weight Duration: 26-52 weeks depending on study Patients losing 5%+: Approximately 30-40% Patients losing 10%+: Less than 10% Patients losing 15%+: Rare Real-World Weight Loss Examples: Starting Weight: 250 pounds Starting Weight: 200 pounds Why Such a Big Difference

So we created a prebiotic fiber supplement powder that could be taken daily, and enjoyed while helping boost GLP-1 levels and promoting health benefits like: Reduces bloating within 30 minutes The feeling of fullness within 30 minutes Promotes regularity of bowel movements VP of Scientific Affairs + education, Dr

J Med Chem (2012) 55(16):7193207

Clear the Confusion: Abbott Juven Powder vs

Great deal with clear testing COAs are solid and price is unbeatable